Lumida
/BRKR
⌘K
Bruker Corp

Bruker Corp

BRKR
$58.23USD↓-1.72%-1.02 today

MARKET CAP

8.9B

P/E (TTM)

34.9x

FWD P/E

23.7x

DAY RANGE

$57 – $59

52W RANGE

$29
$65

AI Summary

Stalk
StalkMedium

BRKR remains in a Stage 2 advance with a bullish medium-term bias supported by higher highs and higher lows alongside rising moving averages, yet recent churning near multi-month resistance indicates a corrective consolidation; short-term timing is neutral as price pulls back into and holds above the 9 and 21 EMAs near the 50 DMA, so execution is best deferred until a pullback into the EMA envelope or defined support zones aligns for entry.

  • ↑BSI bookings rose high single digits, led by biopharma demand
  • ↑Introduced MyGenius Pro and expanded AI-driven metrology offerings
  • ↓U.S. academic orders set to drop 20–25%, pressuring revenue
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Bruker Corporation (NASDAQ: BRKR) is a leading provider of scientific instruments and high-performance analytical solutions, serving diverse markets including life sciences, biopharma, and industrial applications. Operating in a competitive and technologically advanced sector, Bruker aims to leverage innovations in space biology, proteomics, and advanced diagnostic technologies to capture a growing share of demand in the post-genomic landscape while expanding its geographic footprint.

Bull says

  • ↑BSI bookings rose high single digits, led by biopharma demand
  • ↑Introduced MyGenius Pro and expanded AI-driven metrology offerings
  • ↑Targeting $140M annual savings to support 300–350bp margin gains
  • ↑Guides FY26 revenue growth of 4–5% after modest Q2 2025 decline
  • ↑APAC and Europe order recovery offsets U.S. academic weakness
  • ↑Robust balance sheet quality and upward analyst revisions bolster outlook

Bear says

  • ↓U.S. academic orders set to drop 20–25%, pressuring revenue
  • ↓Tariffs and currency swings expected to reduce operating profit by ~$90M
  • ↓Q1 non-GAAP operating margin fell 250bp YoY to 10.2%, showing margin squeeze
  • ↓Q1 EPS down 34% YoY to $0.31, underscoring earnings weakness
  • ↓Elevated short interest signals investor skepticism
  • ↓Execution risk on delivering $140M savings amid headwinds

Investment themes with BRKR

Medical Devices↑ +0.44%

Devices and instruments for medical treatment

MEDP · RDNT · OPCH

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-08-2026neutral

Transcript signals

Bull points

  • pleased that our first quarter 26 financial performance came in well ahead of expectations.
  • The rapidly increasing need for computing power and emerging applications for artificial intelligence provide strong secular tailwinds in semi-metrology.
  • Our security detection business has grown from a niche business a few years ago to about $70 million in revenue expected this year.

Bear points

  • While U.S. academic demand, tariffs, and currency headwinds have continued to pressure our year-over-year results
  • Our Q1 reported revenues of $823 million increased 2.7% year over year, an FX tailwind of 4.5 and a growth contribution from M&A of 2.6%, more than offset an organic decline of 4.4%. BSI segment revenues were down 5% organically.
  • Despite significant macro and foreign exchange headwinds in the quarter, we delivered financial performance ahead of expectations
Read full transcript analysis ›